Nurtec copay card trial#

For more information about NURTEC ODT, visit About Migraine Nearly 40 million people in the U.S. suffer from migraine and the World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. The recommended dose of NURTEC ODT is 75 mg, taken as needed, up to once daily. NURTEC ODT is a CGRP receptor antagonist that works by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. The activity of the neuropeptide CGRP is thought to play a causal role in migraine pathophysiology. Food and Drug Administration (FDA) for the acute treatment of migraine in adults. Hypersensitivity reactions with dyspnea and severe rash, including delayed serious hypersensitivity days after administration, occurred in less than 1% of subjects taking NURTEC ODT in clinical studies.Ībout NURTEC ODT NURTEC™ ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. NURTEC ODT is contraindicated in patients with a history of hypersensitivity to rimegepant, NURTEC ODT, or to any of its components. More information about the FDA approval is available here. In the pivotal Phase 3 trial, NURTEC ODT was generally well tolerated the most common adverse reaction was nausea (2%) in patients who received NURTEC ODT compared to 0.4% of patients who received placebo.

Nurtec copay card trial#

Drug and Enforcement Administration. The FDA approval of NURTEC ODT is based on results from the pivotal Phase 3 clinical trial (Study 303) and the long-term, open-label safety study (Study 201). NURTEC ODT is not an opioid or narcotic, does not have addiction potential and is not scheduled as a controlled substance by the U.S. More information about NURTEC ODT and its patient savings program can be found at 1-833-4NURTEC, and the NURTEC ODT Twitter community.Ī single dose of NURTEC ODT 75 mg provides fast pain relief, returns patients to normal function within one hour, and delivers sustained efficacy that lasts up to 48 hours for many patients, allowing people with migraine to get back to living their lives. Jones added, 'We are working closely with the advocacy community and physicians to share these resources with their constituents and ensure people with migraine have access to the resources they need.' BJ Jones, Chief Commercial Officer of Migraine and Common Diseases commented, 'We are committed to helping ensure people with migraine have access to the treatments they need and therefore have established a comprehensive, best-in-class suite of patient affordability and access programs, including a patient starter kit and a co-pay savings card which will allow patients with commercial insurance to pay as little as $0 for Nurtec ODT.' Mr.